v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04565379 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : Jan. 29, 2022, 11:30 a.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : Jan. 29, 2022, 11:30 a.m. Source : ClinicalTrials.gov |
David Song, shsong@shaperon.com (PI email not reported) |
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2020-09-25 |
Recruitment status
Last imported at : Jan. 29, 2022, 11:30 a.m. Source : ClinicalTrials.gov |
Completed |
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Blind label |
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
multi-center |
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment |
Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
inclusion criteria male or female subjects aged between 18≤ and <80 years old laboratory-confirmed sars-cov-2 infection by pcr test for the first time within 144 hours prior to randomization diagnosis of pneumonia based on: radiographic infiltrates by imaging (chest x-ray, ct scan) and 3 of the following clinical symptoms: new onset cough, fever, fatigue, sputum (all day), tachypnea, dyspnea, pleuritic chest pain and crp value > 10 mg/l patients with blood leukocyte count > 4.0 x 109 /l and lymphocyte count > 0.7 x 109 l patients with spo2 ≤ 94% on room air or pa02/fi02 ratio < 300mghg at screening patients capable to give consent and who have signed the informed consent form before any trial related assessment. medically accepted effective contraception for women of childbearing potential (wocbp) which should be continued until at least 90 days after the last dose of trial treatment. patients with news2 score > 7 exclusion criteria alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal. reduced renal function with estimated glomerular filtration rate (egfr) < 30 ml/min or hemodialysis or hemofiltration. pregnancy or breast feeding. evidence of multiorgan failure steroid treatment by any reason within 72 hours prior to enrolment participation in any other clinical trial of an experimental agent treatment for covid-19 physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely. |
Exclusion criteria
Last imported at : March 19, 2021, 12:31 a.m. Source : ClinicalTrials.gov |
None |
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
3 |
Funding
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Shaperon |
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
79 |
Countries
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Romania |
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Severe/critical disease at enrollment |
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
7: Severe/critical disease at enrollment |
Total sample size
Last imported at : Jan. 29, 2022, 11:30 a.m. Source : ClinicalTrials.gov |
64 |
primary outcome
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Difference in Time to Clinical Improvement (TTCI) between the 2 treatments and the placebo group (in days) |
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m. Source : ClinicalTrials.gov |
Phase 2 |
Arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 914, "treatment_name": "Nusepin", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 914, "treatment_name": "Nusepin", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}] |